FDA Declines to Approve Rare Disease Drugs Under Priority Voucher Program
- February 20, 2026
The Food and Drug Administration (FDA) has declined to grant accelerated approval under its newly launched National Priority Voucher pilot program to Disc Medicine, Inc.’s treatment for erythropoietic protoporphyria, a rare genetic disorder that causes extreme sensitivity to sunlight.
ARTICLE TAGS
You must be logged in to access this content.